A5045158511- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Pediatric Urology and Nephrology Studies
- Epigenetics and DNA Methylation
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Urinary Tract Infections Management
- Cancer Immunotherapy and Biomarkers
- Pelvic floor disorders treatments
- Multiple and Secondary Primary Cancers
- Cardiac, Anesthesia and Surgical Outcomes
- Ureteral procedures and complications
- Economic and Financial Impacts of Cancer
- Pelvic and Acetabular Injuries
- Molecular Biology Techniques and Applications
- Organ Donation and Transplantation
- Digestive system and related health
- Global Cancer Incidence and Screening
- Urologic and reproductive health conditions
- Cancer Research and Treatments
Levine Cancer Institute
2021-2024
Carolinas Medical Center
2022-2024
The University of Texas MD Anderson Cancer Center
2018-2024
Atrium Medical Cente
2023
New York Proton Center
2014-2018
Columbia University Irving Medical Center
2015-2018
New York Hospital Queens
2016-2018
NewYork–Presbyterian Hospital
2016-2018
United Arab Emirates University
2016
Texas Health Dallas
2016
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that associated with poor outcomes however given its rarity, little known outside institutional reports. We sought to use population-level database assess survival in patients treated surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases MPBC UC using International Classification Disease-O-3 morphologic codes...
We evaluated the discordance between ureteroscopic biopsy and surgical pathology findings for grading staging upper tract urothelial carcinoma. also sought to establish preoperative predictors of aggressive tumors.We retrospectively reviewed records 314 patients who underwent followed by management carcinoma from 2000 2016 at a total 3 institutions. Our primary outcomes were muscle invasive (pT2 or greater) disease upgrading clinical low grade tumors pathological high grade.At 61% had 21%...
We report the outcomes in patients with muscle invasive bladder cancer from 2 institutions who experienced a clinically complete response to neoadjuvant platinum based chemotherapy and elected active surveillance. It was unknown whether conservative treatment could be safely implemented these patients.We retrospectively reviewed records of at our surveillance following transurethral resection tumors 2001 2017. A defined as absent tumor on post-chemotherapy tumor, negative cytology normal...
No AccessJournal of UrologyAdult Urology1 Jun 2021Contemporary Outcomes Patients with Nonmuscle-Invasive Bladder Cancer Treated bacillus Calmette-Guérin: Implications for Clinical Trial DesignThis article is commented on by the following:Editorial CommentEditorial Comment Justin T. Matulay, Roger Li, Patrick J. Hensley, Nathan A. Brooks, Vikram M. Narayan, H. Barton Grossman, Neema Navai, Colin P. N. Dinney, and Ashish Kamat MatulayJustin Matulay http://orcid.org/0000-0002-2467-5710...
You have accessJournal of UrologyParadigm-shifting, Practice-changing Clinical Trials in Urology (P2)1 May 2024P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY Andrea Necchi, Siamak Daneshmand, Giuseppe Simone, Evanguelos Xylinas, David S. Morris, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence H. Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Christopher J. Cutie, Hussein...
To prevent avoidable treatment and make more informed care decisions about small renal masses, the use of mass biopsies has increased since early 2000s. In April 2017, Atrium Health Carolinas Medical Center began requiring before all percutaneous thermal ablation procedures for masses. We aim to determine effect this preablation biopsy mandate on decisions.Our study is a retrospective analysis prospectively managed database designed track patients with masses presented at Kidney Tumor...
<ns4:p>Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited relatively indolent papillary tumor with low potential for progression beyond this stage muscle-invasive prone distant metastasis. The former best treated as conservatively possible, whereas latter requires aggressive surgical intervention adjuvant therapies in order provide clinical outcomes. Risk stratification traditionally uses clinicopathologic features of...
No AccessJournal of UrologyAdult Urology1 Sep 2015Predicting Renal Parenchymal Loss after Nephron Sparing Surgery Alexa Meyer, Solomon L. Woldu, Aaron C. Weinberg, Gregory R. Thoreson, Phillip Pierorazio, Justin T. Matulay, Mitchell Benson, G. Joel DeCastro, and James M. McKiernan MeyerAlexa Meyer Columbia University Medical Center, New York, York , WolduSolomon Woldu WeinbergAaron Weinberg ThoresonGregory Thoreson Texas Southwestern Dallas, PierorazioPhillip Pierorazio Johns Hopkins...
Background: Bladder-sparing treatment of muscle invasive bladder cancer (MIBC) with systemic chemotherapy plus transurethral resection tumors (TURBT) is increasingly seen in the literature -both case series and subanalyses patients who opt out or are unfit for radical cystectomy (RC).Survival outcomes among these often impressive, but typically small retrospective studies from single institutions therefore limited clinical value.Objectives: Our aim to summarize regarding definitive MIBC...
You have accessJournal of UrologyCME1 Apr 2023LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 COMBINATION CETRELIMAB, TAR-200, OR CETRELIMAB ALONE Siamak Daneshmand, Michiel S van der Heijden, Joseph M Jacob, Andrea Necchi, Evanguelos Xylinas, David Morris, Philip Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T Matulay, Laurence H Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Shu...
To determine whether perioperative blood transfusion is associated with worse 30-day postoperative outcomes in radical cystectomy patients.Utilizing the National Surgical Quality Improvement Program database, we identified 2934 patients diagnosed bladder cancer (International Classification of Diseases Ninth Revision codes 188-188.9) who underwent (Current Procedure Terminology 51570, 51575, 51580, 51585, 51590, 51595, 51596) between 2005 and 2013. Patients were stratified by status assessed...
Aims To analyze patient characteristics, complications, and surgical trends in vesicovaginal fistulas (VVF) from a national database. Methods Current Procedural Terminology was used to identify patients undergoing VVF repair the American College of Surgeons National Surgical Quality Improvement Project (NSQIP) Characteristics treatments were identified. Logistic regression characteristics associated with complications. Results From 2006 2013, 200 underwent repair. Mean age 50.3 ± 12.3 years....
Objectives To evaluate if the obesity paradox, wherein portends worse overall prognosis for a disease but improved outcomes patients receiving immunotherapy, exists bacillus Calmette–Guérin (BCG) in contemporary cohort. Patients and Methods We performed an Institutional Review Board‐approved database review to identify with non‐muscle‐invasive bladder cancer (NMIBC) completing at least induction course of BCG. Clinicopathological variables collected included: body mass index (BMI),...